The importance of autologous transplantation in multiple myeloma

Česká verzia

Authors: L. Pour ¹; R. Hájek ^1,2; Z. Adam ¹; M. Krejčí ¹; J. Vorlíček ¹
Authors place of work: Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc. ¹; Babákův výzkumný institut, Výzkumné pracoviště MU Brno a FN Brno, vedoucí centra prof. MUDr. Roman Hájek, CSc. ²
Published in the journal: Vnitř Lék 2009; 55(9): 767-772
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Summary

Several randomized clinical trials in multiple myeloma (MM) completed in the last two decades have clearly shown that high-dose chemotherapy with hematopoietic stem cell support significantly increases the number of complete remissions and median overall survival in comparison to conventional chemotherapy. The median survival of MM patients treated with conventional chemotherapy is approximately 4 years in contrast to 5 to 6 years with autologous transplantation. Although high-dose chemotherapy with autologous transplantation is not curative and most patients will eventually relapse, more than 20% of patients treated using this strategy experience survival longer than 10 years. Thus, autologous transplantation is the preferred treatment option for all eligible patients with MM.

Key words:
multiple myeloma – autologous transplantation – long-term results

Zdroje

1. Adam Z, Bačovský J, Flochová E et al. Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a experty Slovenské republiky pro diagnostiku a léčbu mnohočetného myelomu. Transfúze Hematol Dnes 2005; 1 (Suppl 1): 3–51.

2. Anagnostopoulos A, Aleman A, Ayers Get al. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Cancer 2004; 100: 2607–2612.

3. Attal M, Harousseau JL, Facon T et al. InterGroupe Francophone du Myélome: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

4. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91–97.

5. Badros A, Barlogie B, Siegel E et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001; 114: 600–607.

6. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

7. Barlogie B, Anaissie E, van Rhee F et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185.

8. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301.

9. Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936.

10. Barlogie B, Tricot GJ, van Rhee F et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.

11. Benson DM Jr, Elder PJ, Lin TS et al. High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma. Leuk Res 2007; 31: 1069–1075.

12. Björkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol 2001; 38: 219–225.

13. Bladé J, Rosiñol L, Sureda A et al. Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA). High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759.

14. Bourhis JH, Bouko Y, Koscielny S et al. European Group for Blood and Marrow Transplantation. Relapse risk after autologous transplantation in patients with newly diagnose myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica 2007; 92: 1083–1090.

15. Breitkreutz I, Lokhorst HM, Raab MS et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294–1299.

16. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.

17. Carreras E, Rosiñol L, Terol MJ et al. Spanish Myeloma Group/PETHEMA: Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007; 13: 1448–1454.

18. Cavo M, Tosi P, Zamagni E et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434–2441.

19. Cavo M, Zamagni E, Tosi P et al. Bologna 2002 study. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39.

20. Craiu A, Saito Y, Limon A et al. Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood 2005; 105: 2235–2238.

21. Deola S, Scaramuzza S, Birolo RS et al. Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells. J Transl Med 2007; 5: 35.

22. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–852.

23. Facon T, Mary JY, Hulin C et al. Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 2007; 370: 1209–1218.

24. Fermand JP, Katsahian S, Divine M et al. Group Myelome-Autogreffe. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233.

25. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

26. Goldschmidt H. Single vs. double high-dose therapy in multiple myeloma: Second analysis of the GMMG–HD2 trial. Haematologica 2005; 90 (Suppl 1): 38.

27. Hajek R, Krejci M, Krivanova A et al. Salvage treatment with melphalan 100 mg/m2 in fulminant progression of multiple myeloma. Haematologica 2007; 2 (Suppl 1). Abstract 262.

28. Hájek R, Pour L, Krejčí M et al. Elektronická forma parametrické registrace dat pro klinický výzkum v praxi v onkologii – případová studie myelomy. Klin Onkol 2004(Suppl): 73–78.

29. Hájek R, Maisnar V, Krejčí M. Thalidomid. Klin Farmakol Farm 2005; 19: 43–46.

30. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505.

31. Harousseau JL, Attal M. High-dose therapy in multiple myeloma. Hematol J 2003; 4: 163–170.

32. Harousseau JL. Stem cell transplanta-tion in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005; 17: 93–98.

33. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

34. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

35. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 2006; 38: 715–720.

36. Koreth J, Cutler CS, Djulbegovic B et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183–196.

37. Krejci M, Buchler T, Hajek R et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164.

38. Krejci M, Hajek R, Adam Z et al. Significant improvement of long-term survival after autologous transplantation in multiple myeloma patients: a single centre experience. Bone Marrow Transplant 2008; 41 (Suppl 1). Abstract 1358.

39. Krivanova A, Hajek R, Krejci M et al. Czech Myeloma Group. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft – a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie 2004; 27: 275–279.

40. Kuglík P, Filková H, Oltová A et al. The significance and current diagnostic options of cytogenetic changes in multiple myeloma. Vnitř Lék 2006; 52 (Suppl 2): 76–78.

41. Lahuerta JJ, Martinez-Lopez J, Grande Cet al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. Br J Haematol 2000; 109: 138–147.

42. Lenhoff S, Hjorth M, Westin J et al. Nordic Myeloma Study Group. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389–396.

43. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al. Dutch-Belgian HOVON; German GMMG.: Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124–127.

44. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983; 2: 822–824.

45. Moreau P, Facon T, Attal M et al. Intergroupe Francophone du Myélome. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731–735.

46. Moreau P, Hullin C, Garban F et al. Intergroupe Francophone du Myélome group. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99–04 protocol. Blood 2006; 107: 397–403.

47. Palumbo A, Bringhen S, Caravita T et al. Italian Multiple Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831.

48. Palumbo A, Bringhen S, Petrucci MT et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052–3057.

49. Ria R, Falzetti F, Ballanti S et al. Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. Hematol J 2004; 5: 118–122.

50. San Miguel JF, Schlag R, Khuageva N et al. MMY-3002 A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma. Blood 2007; 110: 31a. Abstract 76.

51. Sonneveld P, van der Holt B, Segeren Cet al. Intensive versus double intensive therapy in untreated multiple myeloma. Update analysis of the randomized phase III HOVON 24 study. Haematologica 2005; 90 (Suppl 1): 37–38.

52. Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779.

53. van de Velde HJ, Liu X, Chen G et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399–1406.